Brief: Transgene/Bioinvent: First Patient Treated In Part B Phase I Trial BT-001 In Combination With Keytruda®

Transgene SA

10/10/2023 06:34

Oct 10 (Reuters) - Transgene SA  TRNG.PA :
    * FIRST PATIENT TREATED IN PART B OF PHASE I TRIAL ASSESSING
THE
NOVEL ONCOLYTIC VIRUS BT-001 IN COMBINATION WITH KEYTRUDA®
(PEMBROLIZUMAB)
    * PHASE I PART B WILL EVALUATE COMBINATION OF BT-001 AND
PEMBROLIZUMAB IN SOLID TUMORS, INCLUDING MELANOMA
    * INCLUSION OF LAST PATIENT IN PART B OF STUDY IS EXPECTED
IN H1
2024.

Source text for Eikon:  ID:nBw47WM7Ma 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))